1. Indications:

Imakin (Imatinib INN) 400 mg is indicated for the treatment of:

• Newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase.
• Ph+ CML in accelerated phase or blast crisis.
• Unresectable or metastatic gastrointestinal stromal tumors (GISTs).

2. Pharmacology:

Imakin (Imatinib INN) 400 mg exerts its pharmacological effects by selectively inhibiting the activity of certain tyrosine kinases, including BCR-ABL, c-KIT, and PDGF-R. These kinases are known to be dysregulated in conditions such as CML and GISTs. By blocking their activity, Imakin inhibits cancer cell proliferation, induces apoptosis (programmed cell death), and suppresses tumor angiogenesis, ultimately leading to tumor regression.

3. Dosage and Administration:

The recommended dosage of Imakin (Imatinib INN) 400 mg may vary depending on the type of cancer being treated and individual patient characteristics. Typically, the prescribed dose is 400 mg taken orally once daily, with a meal and a full glass of water. Treatment should continue as long as the patient experiences clinical benefit and tolerates the medication well.

4. Interaction:

Imakin (Imatinib INN) 400 mg may interact with other medications, including:

• Strong CYP3A4 inhibitors or inducers: Co-administration with drugs that affect CYP3A4 metabolism may alter the plasma concentration of Imakin.
• Acid-reducing agents: Concurrent use of proton pump inhibitors (PPIs) or H2-receptor antagonists may decrease the absorption of Imakin, potentially reducing its efficacy.

Patients should inform their healthcare provider about all medications they are taking, including prescription, over-the-counter, and herbal products, to avoid potential interactions.

5. Side Effects:

Common side effects associated with Imakin (Imatinib INN) 400 mg may include:

• Nausea
• Fatigue
• Edema (fluid retention)
• Muscle cramps
• Skin rash
• Diarrhea

Patients should report any persistent or severe side effects to their healthcare provider for further evaluation and management.

6. Precautions and Warnings:

Before using Imakin (Imatinib INN) 400 mg, patients should be aware of the following precautions:

• Imakin may cause myelosuppression, including thrombocytopenia, neutropenia, and anemia. Patients should undergo regular monitoring of blood counts during treatment.
• Hepatotoxicity, including liver function abnormalities, has been reported with Imakin. Liver function tests should be performed before starting treatment and periodically thereafter.
• Imakin may prolong the QT interval, increasing the risk of arrhythmias. Electrocardiograms (ECGs) should be monitored regularly, especially in patients with pre-existing cardiac conditions.

7. Overdose Effects:

In case of overdose with Imakin (Imatinib INN) 400 mg, supportive care should be initiated, and symptomatic treatment may be administered as necessary. There is no specific antidote for Imakin overdose, and patients should seek immediate medical attention if overdose is suspected.